share_log

Chardan Capital Maintains Buy on Arbutus Biopharma, Raises Price Target to $5

Chardan Capital Maintains Buy on Arbutus Biopharma, Raises Price Target to $5

Chardan Capital維持對arbutus biopharma的買入評級,將目標價格提高到5美元
Benzinga ·  11/20 18:58  · 評級/大行評級

Chardan Capital analyst Keay Nakae maintains Arbutus Biopharma (NASDAQ:ABUS) with a Buy and raises the price target from $4.5 to $5.

Chardan Capital分析師Keay Nakae維持對arbutus biopharma(NASDAQ:ABUS)的買入評級,並將目標股價從$4.5上調至$5。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論